Skip to main content
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

  • Register
  • Log in
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
  • AACR Publications
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in

Search

  • Advanced search
Cancer Research
Cancer Research

Advanced Search

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Focus on Computer Resources
    • 75th Anniversary
    • Meeting Abstracts
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • OnlineFirst
    • Editors' Picks
    • Citations
    • Author/Keyword
  • News
    • Cancer Discovery News
Experimental and Molecular Therapeutics

Abstract 3631: A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks

Sebastian M. Spencer, Kaushlendra Tripathi, Erhong Meng, Jennifer Scalici, Rodney P. Rocconi and Komaraiah Palle
Sebastian M. Spencer
University of South Alabama Mitchell Cancer Institute, Mobile, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kaushlendra Tripathi
University of South Alabama Mitchell Cancer Institute, Mobile, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Erhong Meng
University of Alabama at Birmingham, Birmingham, AL.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jennifer Scalici
University of South Alabama Mitchell Cancer Institute, Mobile, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rodney P. Rocconi
University of South Alabama Mitchell Cancer Institute, Mobile, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Komaraiah Palle
University of South Alabama Mitchell Cancer Institute, Mobile, AL;
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1538-7445.AM2015-3631 Published August 2015
  • Article
  • Info & Metrics
Loading
Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA

Abstract

Ovarian cancer (OVCA) is the deadliest of all the reproductive cancers, affecting over 22,000 lives of women annually in the USA alone. In spite of their initial promising response rates to platinum drugs, more than 70% of patients relapse and die with the advanced disease. An important factor contributing to the poor outcomes in OVCA is platinum resistance (PR) and disease recurrence. Therefore, it is vital to understand the molecular mechanisms contributing to tumor resistance to platinum drugs and disease recurrence. Our preliminary studies identified aberrant activation of Hedgehog (Hh) signaling in advanced stage tumors and in OVCA cells, particularly those that are resistant to platinum agents. Further genetic and biochemical studies revealed altered expression of several cell cycle checkpoint and DNA repair genes involved in repair of platinum drug-induced DNA damage in these tumors and cell lines. Aberrant Hh signaling is implicated in the regulation of several signaling pathways including cell cycle, differentiation and DNA repair networks. Hence, we hypothesized that inhibition of Hh signaling could affect the expression of altered DNA damage response and repair networks and sensitize OVCA cells to platinum therapy. To this end, we evaluated two small molecule inhibitors of Hh signaling that target SMO (BMS-833923) and GLI transcription factors (GANT61) either alone or in combination with carboplatin in several OVCA cell lines by clonogenic and MTS cell survival assays. The therapeutic efficacy was assessed by calculating combination index (CI) values using CalcuSyn software. Simultaneously, we have also assessed the status of Hh signaling and several DNA damage response and repair networks that respond to platinum drugs. Interestingly, both the inhibitors of Hh signaling attenuated OVCA cells’ growth and their ability to form colonies. Consistent with this, inhibition of Hh signaling alone induced replication stress associated DNA damage responses (as evidenced by γH2AX foci) and compromised ATR-mediated cell cycle checkpoint responses. Similarly, combination treatment of Hh inhibitor (either SMO inhibitor or GLI inhibitor) with carboplatin potentiated the DNA damage induced by carboplatin and its cytotoxic effects in several ovarian cancer cell lines. Additionally, evaluation of combination treatments efficacies was confirmed in isogenic platinum sensitive (A2780) and resistant (A2780/CP70) OVCA cell lines. Moreover, analysis of combination therapeutic indexes revealed synergistic effects by demonstrating the CI values in the range of 0.3 to 0.49 (synergy defined as CI <1) at multiple dosage combinations. Collectively, our studies suggest the combination of Hh signaling inhibitors with carboplatin could be an effective therapeutic modality in synergistic killing of ovarian cancer cells and overcoming platinum resistance.

Citation Format: Sebastian M. Spencer, Kaushlendra Tripathi, Erhong Meng, Jennifer Scalici, Rodney P. Rocconi, Komaraiah Palle. A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks. [abstract]. In: Proceedings of the 106th Annual Meeting of the American Association for Cancer Research; 2015 Apr 18-22; Philadelphia, PA. Philadelphia (PA): AACR; Cancer Res 2015;75(15 Suppl):Abstract nr 3631. doi:10.1158/1538-7445.AM2015-3631

  • ©2015 American Association for Cancer Research.
Previous
Back to top
Cancer Research: 75 (15 Supplement)
August 2015
Volume 75, Issue 15 Supplement
  • Table of Contents
  • Index by Author

Sign up for alerts

Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Abstract 3631: A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks
(Your Name) has forwarded a page to you from Cancer Research
(Your Name) thought you would be interested in this article in Cancer Research.
Citation Tools
Abstract 3631: A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks
Sebastian M. Spencer, Kaushlendra Tripathi, Erhong Meng, Jennifer Scalici, Rodney P. Rocconi and Komaraiah Palle
Cancer Res August 1 2015 (75) (15 Supplement) 3631; DOI: 10.1158/1538-7445.AM2015-3631

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Abstract 3631: A novel combination of Hedgehog inhibitors with carboplatin exhibits synergy in ovarian cancer treatment by altered regulation of DNA repair networks
Sebastian M. Spencer, Kaushlendra Tripathi, Erhong Meng, Jennifer Scalici, Rodney P. Rocconi and Komaraiah Palle
Cancer Res August 1 2015 (75) (15 Supplement) 3631; DOI: 10.1158/1538-7445.AM2015-3631
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
Advertisement

Related Articles

Cited By...

More in this TOC Section

Experimental and Molecular Therapeutics

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Proffered Abstracts

  • Abstract SY14-03: Anaplastic lymphoma kinase (ALK): Normal biology and role in hematopoietic malignancies
  • Abstract SY18-01: Targeting the p53-MDM2 interaction for cancer therapy
  • Abstract SSY01-04: Discovery and validation of genome-wide genetic signatures of chemotherapy susceptibility: A translational model
Show more 3

Poster Presentations - Targeting Cell Death and DNA Repair

  • Abstract 3621: Deubiquitination of AXIN1 by USP9X promotes apoptosis in melanoma in response to BRAF or MEK inhibition
  • Abstract 3614: The anti-tumor effect of antimalarial chloroquine on endometrial cancer cells is dependent on autophagy inhibition
  • Abstract 3637: Delivery of an epigenetic agent using a microparticle drug delivery system
Show more 3
  • Home
  • Alerts
  • Feedback
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians
  • Reviewers

About Cancer Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2018 by the American Association for Cancer Research.

Cancer Research Online ISSN: 1538-7445
Cancer Research Print ISSN: 0008-5472
Journal of Cancer Research ISSN: 0099-7013
American Journal of Cancer ISSN: 0099-7374

Advertisement